Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial
Stefan Bielack(Klinik und Poliklinik für Kinder- und Jugendmedizin), Mark L. Bernstein(Centre Hospitalier Universitaire Sainte-Justine), Reinhard Windhager(Orthopädische Universitätsklinik), Carol D. Morris(Memorial Sloan Kettering Cancer Center), Joachim Gerß, Pancras C.W. Hogendoorn(Leiden University Medical Center), Beatrice Seddon(Helios Klinikum Emil von Behring), Trude Butterfaß‐Bahloul(University Hospital Münster), Susan Picton(Helios Klinikum Emil von Behring), Henk van den Berg(Emma Kinderziekenhuis), Paul A. Meyers(Memorial Sloan Kettering Cancer Center), Helen Nadel(Helios Klinikum Emil von Behring), Daniel Baumhoer(University Hospital of Basel), Per‐Ulf Tunn(Helios Klinikum Emil von Behring), Gordana Jovic(MRC Clinical Trials Unit at UCL), Gabriele Calaminus(University Hospital Bonn), Hans Gelderblom(Leiden University Medical Center), K. Helmke(Altonaer Kinderkrankenhaus), Catharina Dhooge(Ghent University Hospital), Richard Görlick(Albert Einstein College of Medicine), Mikael Eriksson(Herlev Hospital), Peter Reichardt(Helios Hospital Berlin-Buch), Mathias Werner(Helios Klinikum Emil von Behring), Tom Böhling(Helsinki University Hospital), Jeremy Whelan(University College London), Allen M. Goorin(Dana-Farber Cancer Institute), R. Lor Randall, Matthew R. Sydes(Helios Klinikum Emil von Behring), Bernadette Brennan(Royal Manchester Children's Hospital), Claudia Deffenbaugh(Helios Klinikum Emil von Behring), Zsuzsanna Pápai(National Institute of Oncology), G. Douglas Letson(Moffitt Cancer Center), Sigbjørn Smeland(Oslo University Hospital), Mark C. Gebhardt(Massachusetts General Hospital), Neyssa Marina(Stanford Medicine), Rajaram Nagarajan(Helios Klinikum Emil von Behring), Peter M. Hoogerbrugge(Helios Klinikum Emil von Behring), Kirsten Sundby Hall(Oslo University Hospital), Mark Krailo(Arcadia), James S. Meyer(Helios Klinikum Emil von Behring), Thomas Kühne(University Hospital of Basel), Marleen Renard, Ching C. Lau(Helios Klinikum Emil von Behring), Heribert Jürgens(University Hospital Münster), Jane Hook(University of Leeds), Maria Michelagnoli(Helios Klinikum Emil von Behring), Leo Kager(St Anna Children's Hospital), Paula J. Schomberg(WinnMed), Lisa A. Teot(Boston Children's Hospital)
Cited by 419
Related Papers
Chronic Health Conditions in Adult Survivors of Childhood Cancer
|New England Journal of Medicine|2006|3.6k
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Cremophor EL
|European Journal of Cancer|2001|1.6k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k